Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROGELIO O BARDINAS RODRIGUEZ

Allopathic & Osteopathic Physicians Family Medicine

NPI
1043458326
CMS profile
934009
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$988.10

60 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $976.54 59
Education $11.56 1

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROGELIO O BARDINAS RODRIGUEZ

NPI 1043458326 · CMS profile ID 934009

Allopathic & Osteopathic Physicians / Family Medicine

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043458326?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROGELIO O BARDINAS RODRIGUEZ, NPI 1043458326, CMS profile ID 934009. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043458326?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ROGELIO O BARDINAS RODRIGUEZ, NPI 1043458326, CMS profile ID 934009. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043458326?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ROGELIO O BARDINAS RODRIGUEZ, NPI 1043458326, CMS profile ID 934009, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1043458326?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

60 matching records · $988.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 60 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 60.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $15.0012/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728619287 CMS
Lilly USA, LLC $17.0912/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728619285 CMS
SANOFI-AVENTIS U.S. LLC $16.2612/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744265107 CMS
Janssen Pharmaceuticals, Inc $20.0311/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719390411 CMS
Janssen Pharmaceuticals, Inc $2.1011/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719390403 CMS
Lilly USA, LLC $12.4811/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728619291 CMS
Lilly USA, LLC $14.2511/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728612649 CMS
GlaxoSmithKline, LLC. $16.2610/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738796227 CMS
Lilly USA, LLC $14.0110/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728606221 CMS
Lilly USA, LLC $18.0910/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728622839 CMS
Lilly USA, LLC $15.0010/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728629457 CMS
Janssen Pharmaceuticals, Inc $15.5210/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719390401 CMS
AstraZeneca Pharmaceuticals LP $16.1710/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736005089 CMS
AstraZeneca Pharmaceuticals LP $11.5610/15/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736454043 CMS
Lilly USA, LLC $19.9810/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753918785 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.0809/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720851450 CMS
Lilly USA, LLC $15.0009/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728622837 CMS
Novo Nordisk Inc $14.3809/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744930421 CMS
SANOFI-AVENTIS U.S. LLC $15.1009/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744265063 CMS
Lilly USA, LLC $18.4009/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728612651 CMS
SANOFI-AVENTIS U.S. LLC $14.8709/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744265073 CMS
Janssen Pharmaceuticals, Inc $15.7209/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719390409 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.8209/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720851455 CMS
Lilly USA, LLC $15.0008/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728626067 CMS
GlaxoSmithKline, LLC. $18.1508/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738477193 CMS
Lilly USA, LLC $19.9708/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728612653 CMS
Novo Nordisk Inc $17.0908/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744874503 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.0608/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720851459 CMS
Janssen Pharmaceuticals, Inc $18.7507/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719390399 CMS
Lilly USA, LLC $15.0007/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728619289 CMS
Lilly USA, LLC $17.6307/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728616023 CMS
AstraZeneca Pharmaceuticals LP $17.1507/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736101297 CMS
SANOFI-AVENTIS U.S. LLC $13.9007/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744265045 CMS
SANOFI-AVENTIS U.S. LLC $17.8107/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744265053 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.5007/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720851465 CMS
Janssen Pharmaceuticals, Inc $12.3007/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719390397 CMS
Kowa Pharmaceuticals America, Inc. $15.0206/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716760479 CMS
SANOFI-AVENTIS U.S. LLC $14.5906/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744265043 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.5006/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720851469 CMS
Novo Nordisk Inc $17.5006/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744780917 CMS
AstraZeneca Pharmaceuticals LP $15.5906/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735764137 CMS
Janssen Pharmaceuticals, Inc $20.0006/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719390407 CMS
SANOFI-AVENTIS U.S. LLC $19.0006/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744265037 CMS
GlaxoSmithKline, LLC. $17.5406/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738674717 CMS
SANOFI-AVENTIS U.S. LLC $16.7605/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744265033 CMS
AstraZeneca Pharmaceuticals LP $15.4505/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736358227 CMS
SANOFI-AVENTIS U.S. LLC $14.6805/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744265031 CMS
Janssen Pharmaceuticals, Inc $22.4005/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719390395 CMS
GlaxoSmithKline, LLC. $22.8204/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738762101 CMS
SANOFI-AVENTIS U.S. LLC $21.9204/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744265029 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,126.57 32
PY2020 $988.10 60
PY2021 $1,191.08 72
PY2022 $972.66 59
PY2023 $639.50 23
PY2024 $20.39 1
PY2025 $172.44 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $30,182.65 12
PY2024 Principal investigator $7,574.54 2
PY2023 Principal investigator $59,383.87 4
PY2022 Principal investigator $198,191.49 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

12 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,000.00 12/19/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220815145
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 12/17/2025 Non-covered Recipient Entity
Alma Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220704471
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 12/17/2025 Non-covered Recipient Entity
Alma Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220704473
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Alma Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220704465
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 11/19/2025 Non-covered Recipient Entity
Alma Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220704467
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 11/19/2025 Non-covered Recipient Entity
Alma Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220704469
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 11/19/2025 Non-covered Recipient Entity
Alma Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220805819
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 11/13/2025 Non-covered Recipient Entity
Alma Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220996888
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Alma Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220704457
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 11/01/2025 Non-covered Recipient Entity
Alma Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220704459
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 11/01/2025 Non-covered Recipient Entity
Alma Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220704461
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 11/01/2025 Non-covered Recipient Entity
Alma Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220704463